Vol 12, Supplement 1 (April 26, 2021): Journal of Gastrointestinal Oncology (Intraperitoneal Chemotherapy for Peritoneal Metastases: HIPEC, EPIC, NIPEC, PIPAC and More)

Editorial

Intraperitoneal chemotherapy for peritoneal metastases: confronting diversity, maximizing benefit
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S1-S4 Full Text (1373) COI Form Open Access Get Permission

Review Article on Gastric Cancer

Hyperthermic intraperitoneal chemotherapy in prevention of gastric cancer metachronous peritoneal metastases: a systematic review
Mikhail Yu. Reutovich, Olga V. Krasko, Oleg G. Sukonko
PDF Pages: S5-S17 Full Text (1410) COI Form Open Access Get Permission

Editorial

Adjuvant HIPEC for gastric cancer
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S18-S19 Full Text (1182) COI Form Open Access Get Permission

Review Article on Gastric Cancer

Review of management and treatment of peritoneal metastases from gastric cancer origin
Israel Manzanedo, Fernando Pereira, Ángel Serrano, Estíbalitz Pérez-Viejo
PDF Pages: S20-S29 Full Text (1873) Reporting Checklist COI Form Open Access Get Permission

Editorial

Knowledgeable case selection results in favorable outcomes
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S30-S31 Full Text (665) COI Form Open Access Get Permission

Review Article on Gastric Cancer

Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens
Andreas Brandl, Aruna Prabhu
PDF Pages: S32-S44 Full Text (2215) COI Form Open Access Get Permission

Editorial

Current data is sufficient to recommend a current standard of care
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S45-S46 Full Text (557) COI Form Open Access Get Permission

Original Article on Gastric Cancer

Surgery with hyperthermic intraperitoneal chemotherapy after response to induction chemotherapy in patients with peritoneal metastasis of gastric cancer
Emel Canbay, Bahar Canbay Torun, Kaan Cosarcan, Cetin Altunal, Bulent Gurbuz, Cagri Bilgic, Canfeza Sezgin, Kerim Kim Kaban, Serpil Yilmaz, Zeliha Yazici
PDF Pages: S47-S56 Full Text (1657) Reporting Checklist COI Form Open Access Get Permission

Editorial

Super-responders to bidirectional neoadjuvant chemotherapy showed prolonged survival
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S57-S58 Full Text (708) COI Form Open Access Get Permission

Review Article on Gastric Cancer

A narrative review of intraperitoneal chemotherapy and cytoreductive surgery (CRS) for peritoneal metastases in gastric cancer
Thomas Boerner, Pompiliu Piso
PDF Pages: S59-S67 Full Text (1330) Reporting Checklist COI Form Open Access Get Permission

Editorial

Aggressive local treatments may prolong survival but do not have curative intent
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S68-S69 Full Text (748) COI Form Open Access Get Permission

Review Article on Gastric Cancer

Intra-operative hyperthermic intraperitoneal chemotherapy for prevention and treatment of peritoneal metastases from gastric cancer: a narrative review
Zhong-He Ji, Ying Zhang, Yan Li
PDF Pages: S70-S78 Full Text (1432) Reporting Checklist COI Form Open Access Get Permission

Editorial

Single institution best recommendation is HIPEC with cisplatin and docetaxel
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S79 Full Text (705) COI Form Open Access Get Permission

Original Article on Pancreas Cancer

Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41
David Padilla-Valverde, Esther García-Santos, Susana Sanchez, Carmen Manzanares, Marta Rodriguez, Lucia González, Alfonso Ambrós, Juana M. Cano, Leticia Serrano, Raquel Bodoque, Teresa Vergara, Jesus Martin
PDF Pages: S80-S90 Full Text (1137) Reporting Checklist Data Sharing Statement COI Form Open Access Get Permission
Hyperthermic intra-operative intraperitoneal chemotherapy as an adjuvant to pancreatic cancer resection
Antonios-Apostolos K. Tentes
PDF Pages: S91-S98 Full Text (1086) COI Form Open Access Get Permission

Review Article on Pancreas Cancer

Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions
Paul H. Sugarbaker, O. Anthony Stuart
PDF Pages: S99-S109 Full Text (1521) Reporting Checklist COI Form Open Access Get Permission

Original Article on Pancreas Cancer

Conversion surgery in patients with pancreatic cancer and peritoneal metastasis
Suguru Yamada, Tsutomu Fujii, Tomohisa Yamamoto, Hideki Takami, Isaku Yoshioka, So Yamaki, Fuminori Sonohara, Kazuto Shibuya, Fuyuhiko Motoi, Satoshi Hirano, Yoshiak Murakami, Hitoshi Inoue, Masamichi Hayashi, Daisuke Hashimoto, Kenta Murotani, Joji Kitayama, Hideki Ishikawa, Yasuhiro Kodera, Mitsugu Sekimoto, Sohei Satoi
PDF Pages: S110-S117 Full Text (2031) Reporting Checklist COI Form Open Access Get Permission

Editorial

Peritoneal progression after pancreaticoduodenectomy is a devastating surgical treatment failure: HIPEC gemcitabine is an option
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S118-S119 Full Text (545) COI Form Open Access Get Permission

Review Article on Appendiceal Malignancy and Colon Cancer

Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7
Peter Cashin, Paul H. Sugarbaker
PDF Pages: S120-S128 Full Text (2825) COI Form Open Access Get Permission

Editorial

The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other HIPEC regimens
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S129-S130 Full Text (869) COI Form Open Access Get Permission

Review Article on Appendiceal Malignancy and Colon Cancer

Sequential postoperative intraperitoneal chemotherapy for colorectal cancer with peritoneal metastases: a narrative review
Peter H. Cashin, Wilhelm Graf
PDF Pages: S131-S135 Full Text (1291) Reporting Checklist COI Form Open Access Get Permission

Editorial

Cashin and Graf: long-term intraperitoneal 5-fluorouracil is superior to adjuvant FOLFOX in a randomized trial
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S136 Full Text (614) COI Form Open Access Get Permission

Review Article on Ovarian Malignancy

Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer
Thomas Boerner, Oliver Zivanovic, Dennis S. Chi
PDF Pages: S137-S143 Full Text (1336) Reporting Checklist COI Form Open Access Get Permission
Intraperitoneal chemotherapy for ovarian cancer with peritoneal metastases, systematic review of the literature and focused personal experience
Federico Coccolini, Paola Fugazzola, Giulia Montori, Luca Ansaloni, Massimo Chiarugi
PDF Pages: S144-S181 Full Text (2251) Reporting Checklist COI Form Open Access Get Permission
Narrative review of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced ovarian cancer: a critical reappraisal of the current evidence
John Spiliotis, Anastasia Prodromidou
PDF Pages: S182-S188 Full Text (1241) Reporting Checklist COI Form Open Access Get Permission

Editorial

Ovarian cancer with peritoneal metastases has many treatment options and HIPEC is here to stay
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S189-S190 Full Text (902) COI Form Open Access Get Permission

Review Article on New Technologies

Omics analyses in peritoneal metastasis—utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review
Christin Lund-Andersen, Annette Torgunrud, Karianne Giller Fleten, Kjersti Flatmark
PDF Pages: S191-S203 Full Text (1694) Reporting Checklist COI Form Open Access Get Permission

Editorial

Genetic targets for cancer control are a reality
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S204-S205 Full Text (584) COI Form Open Access Get Permission

Review Article on New Technologies

Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research
Checca Bakkers, Geert A. A. M. Simkens, Ignace H. J. T. De Hingh
PDF Pages: S206-S213 Full Text (1013) COI Form Open Access Get Permission

Editorial

The options are neoadjuvant, adjuvant, or no chemotherapy at all: further data is needed
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S214-S215 Full Text (626) COI Form Open Access Get Permission

Review Article on New Technologies

New insights in the pathology of peritoneal surface malignancy
Norman John Carr
PDF Pages: S216-S229 Full Text (2963) COI Form Open Access Get Permission

Editorial

A model for accurate histopathologic assessment refines treatment options
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S230 Full Text (547) COI Form Open Access Get Permission

Review Article on New Technologies

Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects
Paul H. Sugarbaker
PDF Pages: S231-S239 Full Text (1932) COI Form Open Access Get Permission

Editorial

Paclitaxel is the pharmacologic near perfect chemotherapy for peritoneal metastases
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S240-S241 Full Text (691) COI Form Open Access Get Permission

Review Article on New Technologies

Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases—a systematic review
Robin J. Lurvink, Koen P. Rovers, Simon W. Nienhuijs, Geert-Jan Creemers, Jacobus W. A. Burger, Ignace H. J. de Hingh
PDF Pages: S242-S258 Full Text (2041) Reporting Checklist COI Form Open Access Get Permission
The emergence of pressurized intraperitoneal aerosol chemotherapy as a palliative treatment option for patients with diffuse peritoneal metastases: a narrative review
Robin J. Lurvink, Kurt Van der Speeten, Koen P. Rovers, Ignace H. J. T. de Hingh
PDF Pages: S259-S270 Full Text (1470) Reporting Checklist COI Form Open Access Get Permission

Editorial

PIPAC may work but more data is needed
Paul H. Sugarbaker, Kurt Van der Speeten
PDF Pages: S271-S272 Full Text (1025) COI Form Open Access Get Permission

Disclosure:

The focused issue was sponsored by the Peritoneal Surface Oncology Group International (PSOGI). Paul H. Sugarbaker and Kurt Van der Speeten served as the unpaid Guest Editors of the focused issue.